Jokath

Timolol and Travoprost, the active ingredients in Jokath, are a beta‑blocker and a prostaglandin analog presented as ocular eye drops for ophthalmic use. They are prescribed to lower intra‑ocular pressure in patients with certain types of glaucoma and ocular hypertension.

GNH USA supplies Jokath as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Jokath is used in the management of ocular conditions that require reduction of intra‑ocular pressure.

Open‑angle glaucoma: lowers intra‑ocular pressure to slow disease progression. Ocular hypertension: reduces pressure to prevent development of glaucoma.

Jokath may cause a range of ocular and systemic reactions.

Common Side Effects: - Eye irritation or burning sensation - Blurred vision - Dry eye or foreign body sensation - Redness of the conjunctiva - Increased eyelash growth or pigmentation changes - Mild headache

Serious or Rare Side Effects: - Severe allergic reaction (e.g., angio‑edema, anaphylaxis) - Significant eye pain or sudden loss of vision - Systemic beta‑blocker effects such as bradycardia, hypotension, or bronchospasm - Uveitis or intra‑ocular inflammation

Before initiating Jokath, clinicians should consider several safety aspects.

Cardiovascular assessment: patients with bradycardia, heart block, or severe asthma may be at increased risk. Respiratory status: avoid in patients prone to bronchospasm due to systemic β‑blockade. Allergy screening: do not use in individuals with known hypersensitivity to beta‑blockers or prostaglandin analogs. Concurrent ocular hypotensives: monitor intra‑ocular pressure when used with other pressure‑lowering agents. Pregnancy and lactation: prescribe only if the potential benefit justifies the potential risk. Store at room temperature: keep in the original container, protect from light and moisture.

Jokath can interact with other medications, requiring careful management.

Major Interactions (Avoid): - Systemic non‑selective beta‑blockers (e.g., propranolol): may cause additive bradycardia or hypotension. - Inhaled β2‑agonists or corticosteroids for asthma: increased risk of bronchospasm. - Other prostaglandin analog eye drops: may amplify ocular side effects.

Moderate Interactions (Monitor Closely): - Topical ocular anesthetics: may enhance corneal irritation. - Combination therapy with carbonic anhydrase inhibitors: monitor intra‑ocular pressure for excessive reduction. - CYP2C9 inhibitors (e.g., fluconazole): may increase travoprost exposure, watch for heightened side effects.